Clinical trials: Myeloma-Multiple
Multiple Myeloma
Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens
This is a phase 2, multicenter, open label, nonrandomized study for patients with MM who will receive treatment with a SC bortezomib-containing combination regimen that does not contain thalidomide or vincristine.
- Trial name
- NCT01695330
- Testing
- Subcutaneous bortezomib
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Oncotherapeutics
Acute Myeloid Leukemia, Multiple Myeloma
Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma
The purpose of this first-in-man Phase I-IIa study is to evaluate the safety and antitumor activity of autologous CD44v6 CAR T-cells in patients with acute myeloid leukemia (AML) and multiple myeloma (MM).
- Trial name
- NCT04097301
- Testing
- MLM-CAR44.1 T-cells at day 0 Single intravenous infusion
- Where
- 3 sites in Czechia, Italy
- Volunteers
- 8 people
- Sponsor
- AGC Biologics S.p.A.
Multiple Myeloma, Breast Cancer
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
The primary objective of this study is to investigate the repeat-dose pharmacokinetic (PK) profile of zoledronic acid when administered every 4 weeks versus every 12 weeks, in patients treated with 9-20 infusions of zoledronic…
- Trial name
- NCT00424983
- Testing
- Zoledronic acid
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- Novartis Pharmaceuticals
Newly Diagnosed, Previously Untreated Multiple Myeloma
PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)
The purpose of the study is to look at subjects who receive Lenalidomide, Dexamethasone, and Elotuzumab and determine if they will have lower surface CS1 expression on malignant plasma cells at the time of progression than those…
- Trial name
- NCT01891643
- Testing
- Lenalidomide, Dexamethasone, Elotuzumab
- Where
- 14 sites in United States, Greece and 2 more
- Volunteers
- 23 people
- Sponsor
- Bristol-Myers Squibb
Relapsed Multiple Myeloma
Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma
The primary objective was to compare progression-free survival in adults with relapsed multiple myeloma who are receiving CRd vs participants receiving Rd in a randomized multicenter setting.
- Trial name
- NCT01080391
- Testing
- Dexamethasone, Lenalidomide, Carfilzomib
- Where
- 127 sites in United States, Austria and 18 more
- Volunteers
- 792 people
- Sponsor
- Amgen
Multiple Myeloma
Study of the Safety and Efficacy of an Investigational Drug in Adult Patients With Multiple Myeloma
The primary goal of the study is to determine the best dose of an investigational drug to give to patients with multiple myeloma and to evaluate the investigational drug's effectiveness as a treatment for multiple myeloma.
- Trial name
- NCT00036140
- Testing
- Investigational drug
- Where
- 5 sites in United States
- Sponsor
- Pfizer
Plasma Cell Myeloma
A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma
Primary Objective: Part A: To evaluate the safety of SAR650984 (isatuximab) in patients with relapsed/refractory multiple myeloma (RRMM).
- Trial name
- NCT02514668
- Testing
- Isatuximab
- Where
- 18 sites in United States, Czechia and 1 more
- Volunteers
- 55 people
- Sponsor
- Sanofi
Multiple Myeloma
Efficacy Study of ZD6474 to Treat Multiple Myeloma Cancer
The primary objective is to assess the efficacy of ZD6474 when given orally to patients with relapsed multiple myeloma. A minimum of 15 and a maximum of 30 evaluable patients will be entered on study
- Trial name
- NCT00047788
- Testing
- ZD6474, VEGF-receptor tyrosine kinase (KDR)
- Where
- 7 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Genzyme, a Sanofi Company
Non-Small Cell Lung Cancer, Multiple Myeloma
Common Safety Follow-up Trial of Tecemotide (L-BLP25)
This is an open-label, common follow-up trial. Subjects who were enrolled in a Merck KGaA, EMD Serono or Merck Serono Japan sponsored trial with tecemotide (L-BLP25) were enrolled in this follow-up trial to continue their…
- Trial name
- NCT01423760
- Testing
- Tecemotide, No intervention
- Where
- Germany
- Volunteers
- 27 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Lymphoma, Breast Neoplasms
Chemotherapy Related Anemia in Patients With Non-Myeloid Malignancies
Chemotherapy can often cause anemia in patients with cancer. Anemia is a low number of red blood cells. The symptoms of anemia may include fatigue, dizziness, headache, chest pain, and shortness of breath.
- Conditions
- Lymphoma, Breast Neoplasms, Lung Neoplasms, Multiple Myeloma
- Trial name
- NCT00036023
- Testing
- darbepoetin alfa
- Sponsor
- Amgen
Multiple Myeloma (MM)
Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma
The purpose of this study is to evaluate the tolerability,safety and efficacy of OPC-415 in patients with relapsed and/or refractory Multiple Myeloma (MM).
- Trial name
- NCT04649073
- Testing
- OPC-415
- Where
- 8 sites in Japan
- Volunteers
- 11 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Refractory Multiple Myeloma (RRMM)
A Real World Study of Elranatamab in Patients With RR Multiple Myeloma in Taiwan
The purpose of this study is to evaluate: What is the real-world effectiveness of elranatamab in patients with relapsed and/or refractory multiple myeloma (RRMM) in Taiwan? What are the baseline and clinical characteristics of…
- Trial name
- NCT07391761
- Testing
- Non intervention
- Where
- 4 sites in Taiwan
- Volunteers
- 1 people
- Sponsor
- Pfizer
Prostatic Neoplasms, Multiple Myeloma
Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies
This study will test the safety, tolerance, and efficacy of different doses of oral gallium maltolate. Patients will receive oral gallium maltolate twice daily for 28-consecutive days followed by 14 days off treatment.
- Conditions
- Prostatic Neoplasms, Multiple Myeloma, Bladder Neoplasms, Lymphoma
- Trial name
- NCT00050687
- Testing
- Gallium maltolate
- Where
- 5 sites in United States
- Sponsor
- Titan Pharmaceuticals
Relapsed or Refractory Multiple Myeloma
A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003
The purpose of this study is to evaluate how well IBI3003 works when compared with the investigator's choice regimen (DPd or PVd or SVd)
- Trial name
- NCT07623798
- Testing
- Pomalidomide Capsules, Bortezomib for Injection, Daratumumab Injection (Subcutaneous Injection)
- Where
- China
- Volunteers
- 255 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Refractory Multiple Myeloma, Recurrent Multiple Myeloma
Safety, Pharmacokinetics and Efficacy Study of Bisthianostat in Refractory or Recurrent Multiple Myeloma Patients
This is a first-in-human study to investigate the safety, tolerability, pharmacokinetics, and efficacy of Bisthianostat in refractory or recurrent multiple myeloma patients.
- Trial name
- NCT03618602
- Testing
- Bisthianostat
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Theorion Pharmaceutical Co Ltd.
Plasma Cell Myeloma
A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)
Primary Objective: To assess the effectiveness, in terms of overall response rate (ORR) of isatuximab patients with RRMM in routine clinical practice, within 12 months To assess other effectiveness parameters such as progression…
- Trial name
- IONA-MM (NCT04458831)
- Testing
- isatuximab SAR650984, Pomalidomide, Dexamethasone
- Where
- 129 sites in United States, Argentina and 19 more
- Volunteers
- 583 people
- Sponsor
- Sanofi
Multiple Myeloma
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
This is a phase 1, multicenter, open-label study evaluating the safety and efficacy of ruxolitinib, steroids and lenalidomide among MM patients who currently show progressive disease.
- Trial name
- NCT03110822
- Testing
- Ruxolitinib Oral Tablet [Jakafi], Lenalidomide, Methylprednisolone
- Where
- 13 sites in United States
- Volunteers
- 134 people
- Sponsor
- Oncotherapeutics
Multiple Myeloma
Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma
This study will be conducted in 2 parts. The phase 1b part will be an international, phase 1b, open-label, dose-escalation assessment of radium-223 dichloride administered with bortezomib and dexamethasone in subjects with…
- Trial name
- NCT02928029
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223), Bortezomib, Dexamethasone
- Where
- 7 sites in United States, South Korea and 1 more
- Volunteers
- 7 people
- Sponsor
- Bayer
Multiple Myeloma
Safety and Dose Determining Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma
This Phase I research study is to test the effects (good and bad) and best dose of BT062 in treating patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT00723359
- Testing
- BT062
- Where
- 4 sites in United States
- Volunteers
- 32 people
- Sponsor
- Biotest Pharmaceuticals Corporation
Multiple Myeloma
Masitinib in Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not FGFR3
This phase 2 study was designed to assess the safety and efficacy of masitinib (AB1010) in patients with relapsing/refractory t(4;14) Multiple Myeloma.
- Trial name
- NCT00866138
- Testing
- masitinib (AB1010)
- Where
- France
- Volunteers
- 24 people
- Sponsor
- AB Science
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.